Business
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a supplemental Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc.
About this update from Biovaxys Technology Corp
[{"type":"text","content":"The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets","length":87,"tagName":"p"},{"type":"text","content":"VANCOUVER, BC, Sept. 29, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a supplemental Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc.","length":574,"tagName":"p"},{"type":"image","alt":"BioVaxys Technology Corp. (PRNewsfoto/BioVaxys Technology Corp.)","displaySize":"","headline":null,"caption":"BioVaxys Technology Corp. (PRNewsfoto/BioVaxys Technology Corp.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":63,"url":"https://media.zenfs.com/en/cnwgroup.com/cca0b1a397afc4499b82a11ef5413aff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9ulMxObQLWtbOLV3qJfMtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/cca0b1a397afc4499b82a11ef5413aff","width":400,"height":63}},"href":"https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Section 12 of the February 11th, 2024 APA is a performance milestone provision for BioVaxys to demonstrate an aggregate capital raise of USD $10M by December 31, 2024. On December 9th, 2024, Horizon and BioVaxys amended the APA by agreeing to delete the reference to "December 31, 2024" found in Section 12 and replacing it with the date of "June 30, 2025."On May 28th, 2025, Horizon and BioVaxys further amended the APA by agreeing to delete the reference to "December 31, 2024" found in Section 12 and replacing it with the date of "June 30, 2025." A revised Amendment of May 29th, 2025, superseded and replaced the Section 12 terms of the APA so that the net performance milestone required to be raised in any form (including, but not limited to equity, grants, licensing fees, or loans) by September 30, 2025 was significantly lowered to USD $2,028,636....